삼성서울병원

Ko En
의료진 검색
찾으실 의료진명을 입력하여 검색해주세요.

혈액종양내과 박준오 교수

진료분야
췌장암, 담도암
진료일정 01 月
날짜
수
01
목
02
금
03
토
04
일
05
월
06
화
07
수
08
목
09
금
10
토
11
일
12
월
13
화
14
수
15
목
16
금
17
토
18
일
19
월
20
화
21
수
22
목
23
금
24
토
25
일
26
월
27
화
28
수
29
목
30
금
31
오전
오후
진료일정 02 月
날짜
토
01
일
02
월
03
화
04
수
05
목
06
금
07
토
08
일
09
월
10
화
11
수
12
목
13
금
14
토
15
일
16
월
17
화
18
수
19
목
20
금
21
토
22
일
23
월
24
화
25
수
26
목
27
금
28
오전
오후
본원외래 본원클리닉 본원육아상담 암병원외래 암병원클리닉 암병원육아상담

학력

학력
2001.02 연세대학교 대학원 의과학과 박사학위 취득
1995.02 연세대학교 대학원 의학과 석사학위 취득
1991.02 연세대학교 의과대학 졸업

경력

경력
2019.04 ~현재 삼성서울병원 정밀의학혁신연구소 소장
2003.03 ~현재 성균관대학교 의과대학 의학과 교수
2002.03 ~현재 삼성서울병원 혈액종양내과 전문의
2015.03 ~ 2021.03 삼성서울병원 암병원 희귀암센터 센터장
2006.02 ~ 2008.02 하버드의대 Dana-Farber Cancer Institute 연수
2001.03 ~ 2002.02 삼성서울병원 혈액종양내과 전임의
1999.03 ~ 2001.02 연세대학교 의과대학 내과학교실 및 연세 암센터 강사
1992.03 ~ 1996.02 연세대학교 의과대학 신촌세브란스병원 내과 전공의
1991.03 ~ 1992.02 연세대학교 의과대학 신촌세브란스병원 인턴

학회활동

학회활동
대한내과학회(1992-현재)
대한암학회 (1995-현재)
대한항암요법연구회 (1999-현재)
미국암연구학회 (American Association Cancer Research) (1999-현재)
미국임상종양학회 (American Society of Clinical Oncology) (1999-현재)
유럽종양내과학회 (European Society of Medical Oncology) (2001-현재)
논문
  • J CACHEXIA SARCOPENI 2024 10.1002/jcsm.13643 Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer Min, JH; Yu, JI; Kim, SH; Kim, YK; Kim, K; Park, HC; Park, JO; Hong, JY; Lee, KT; Lee, KH; Lee, JK; Park, JK; Choi, JH; Heo, JS; Han, IW; Kim, H; Shin, SH; Yoon, SJ; Woo, SY
    View PubMed
  • EUR J CANCER 2024 10.1016/j.ejca.2024.114312 Prediabetes persistence or remission and subsequent risk of gallbladder cancer: A nationwide cohort study Park, JH; Hong, JY; Han, KYD; Park, YS; Park, JO; Lim, HY; Shen, JJ
    View PubMed
  • PATHOL RES PRACT 2024 10.1016/j.prp.2024.155473 Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis Choi, DH; Jang, HL; Lim, SH; Kim, ST; Hong, JY; Park, SH; Park, JO; Kim, DG; Kim, KM; Lee, J
    View PubMed
  • LANCET GASTROENTEROL 2024 10.1016/S2468-1253(24)00095-5 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1) : updated overall survival from a randomised phase 3 study Oh, D; He, AR; Bouattour, M; Okusaka, T; Qin, SK; Chen, LT; Kitano, M; Lee, CK; Kim, JW; Chen, MH; Suksombooncharoen, T; Ikeda, M; Lee, MA; Chen, JS; Potemski, P; Burris, HA; Ostwal, V; Tanasanvimon, S; Morizane, C; Zaucha, RE; Mcnamara, MG; Avallone, A; Cundom, JE; Breder, V; Tan, B; Shimizu, S; Tougeron, D; Evesque, L; Petrova, M; Zhen, DB; Gillmore, R; Gupta, VG; Dayyani, F; Park, JO; Buchschacher, GL Jr; Rey, F; Kim, H; Wang, J; Morgan, C; Rokutanda, N; Zotkiewicz, M; Vogel, A; Valle, JW
    View PubMed
  • BMC CANCER 2024 10.1186/s12885-024-12584-0 Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial Park, JO; Feng, YH; Su, WC; Oh, D; Keam, B; Shen, L; Kim, SW; Liu, XF; Liao, HM; Qing, M; Zhang, C; Qian, JQ; Tang, XD; Li, P; Triantos, S; Sweiti, H
    View PubMed
  • ESMO OPEN 2024 10.1016/j.esmoop.2024.103647 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer Chen, LT; Vogel, A; Hsu, C; Chen, MH; Fang, W; Pangarsa, EA; Sharma, A; Ikeda, M; Park, JO; Tan, CK; Regala, E; Tai, D; Tanasanvimon, S; Charoentum, C; Chee, CE; Lui, A; Sow, J; Oh, DY; Ueno, M; Ramaswamy, A; Jeo, WS; Zhou, J; Curigliano, G; Yoshino, T; Bai, LY; Pentheroudakis, G; Chiang, NJ; Cervantes, A; Chen, JS; Ducreux, M
    View PubMed
  • CLIN TRANSL MED 2024 10.1002/ctm2.1629 An exosome-based liquid biopsy signature for therapeutic response prediction in metastatic gastric cancer Okuno, K; Watanabe, S; Hur, H; Lee, J; Park, JO; Tokunaga, M; Tanabe, M; Kinugasa, Y; Goel, A
    View PubMed
  • LANCET ONCOL 2024 10.1016/S1470-2045(24)00140-2 Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINYPanTumor01): an international, phase 2 study Li, BT; Meric-Bernstam, F; Bardia, A; Naito, Y; Siena, S; Aftimos, P; Anderson, I; Curigliano, G; de Miguel, M; Kalra, M; Oh, D; Park, JO; Postel-Vinay, S; Rha, SY; Satoh, T; Spanggaard, I; Michelini, F; Smith, A; Machado, KK; Saura, C
    View PubMed
  • HEPATOLOGY 2024 10.1097/HEP.0000000000000965 Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial Oh, DY; Ikeda, M; Lee, CK; Rojas, C; Hsu, CH; Kim, JW; Shen, L; Furuse, J; Park, JO; Borad, M; de Braud, F; Bridgewater, J; Lee, SS; Moehler, M; Audhuy, F; Osada, M; Sato, M; Yoo, C
    View PubMed
  • CLIN TRANSL RAD ONCO 2024 10.1016/j.ctro.2024.100732 Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy Kim, K; Park, HC; Yu, JI; Park, JO; Hong, JY; Lee, KT; Lee, KH; Lee, JK; Park, JK; Heo, JS; Shin, SH; Min, JH; Kim, K; Han, IW
    View PubMed
  • BIOMEDICINES 2023 10.3390/biomedicines11123264 Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data Lim, SH; Jung, J; Hong, JY; Kim, ST; Park, SH; Park, JO; Kim, KM; Lee, J
    View PubMed
  • SCI ADV 2023 10.1126/sciadv.adk1098 Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer Hyung, S; Ko, J; Heo, YJ; Blum, SM; Kim, ST; Park, SH; Park, JO; Kang, WK; Lim, HY; Klempner, SJ; Lee, J
    View PubMed
  • J NATL COMPR CANC NE 2023 10.6004/jnccn.2023.7060 Smoking Cessation and Pancreatic Cancer Risk in Individuals With Prediabetes and Diabetes: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, YS; Park, JO
    View PubMed
  • ANTICANCER RES 2023 10.21873/anticanres.16607 Pemetrexed and Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer Who Failed Gemcitabine-containing Chemotherapy: A Phase II Single-arm Prospective Study Lim, SH; Hong, JY; Park, JO; Park, YS; Kim, ST
    View PubMed
  • JCO PRECIS ONCOL 2023 10.1200/PO.22.00537 Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis Jung, J; Kim, ST; Ko, J; Hong, JY; Park, JO; Ha, SY; Lee, J
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01740 Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study Park, JH; Hong, JY; Shen, JJ; Han, K; Park, JO; Park, YS; Lim, HY
    View PubMed
  • LANCET 2023 10.1016/S0140-6736(23)00727-4 Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial Kelley, RK; Ueno, M; Yoo, C; Finn, RS; Furuse, J; Ren, ZG; Yau, T; Klumpen, HJ; Chan, SL; Ozaka, M; Verslype, C; Bouattour, M; Park, JO; Barajas, O; Pelzer, U; Valle, JW; Yu, L; Malhotra, U; Siegel, AB; Edeline, J; Vogel, A
    View PubMed
  • THER ADV GASTROENTER 2023 10.1177/17562848231170484 The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation Jeong, SY; Hong, JY; Park, JO; Park, YS; Lim, HY; Jang, JY; Jeon, Y; Kim, ST
    View PubMed
  • J CLIN ONCOL 2023 10.1200/JCO.22.01134 Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial Tempero, MA; Pelzer, U; O'Reilly, EM; Winter, J; Oh, D; Li, CP; Tortora, G; Chang, HM; Lopez, CD; Bekaii-Saab, T; Ko, AH; Santoro, A; Park, JO; Noel, MS; Frassineti, GL; Shan, YS; Dean, A; Riess, H; Van Cutsem, E; Berlin, J; Philip, P; Moore, M; Goldstein, D; Tabernero, J; Li, MY; Ferrara, S; Le Bruchec, Y; Zhang, G; Lu, B; Biankin, AV; Reni, M
    View PubMed
  • CELL DEATH DIS 2023 10.1038/s41419-023-05630-5 Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-beta signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors Hong, EJ; Barczak, W; Park, S; Heo, JS; Ooshima, A; Munro, S; Hong, CP; Park, J; An, H; Park, JO; Park, SH; La Thangue, NB; Kim, SJ
    View PubMed
  • CANCER MED-US 2023 10.1002/cam4.5530 Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers Kim, JE; Kim, H; Kim, B; Chung, HG; Chung, HH; Kim, KM; Kim, SH; Jeong, WK; Kim, YK; Min, JH; Heo, JS; Han, IW; Shin, SH; Park, HC; Yu, JI; Park, JO; Kim, ST; Hong, JY; Lee, SH; Lee, KH; Lee, JK; Lee, KT; Jang, KT; Park, JK
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2021.1527 A Phase II Study of Preoperative Chemoradiotherapy with Capecitabine Plus Simvastatin in Patients with Locally Advanced Rectal Cancer Jo, H; Kim, ST; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Il Yu, J; Park, HC; Choi, DH; Park, Y; Cho, YB; Huh, JW; Yun, SH; Kim, HC; Lee, WY; Kang, WK
    View PubMed
  • ANN SURG 2022 10.1097/SLA.0000000000004993 Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma Nishiwada, S; Cui, Y; Sho, M; Jun, E; Akahori, T; Nakamura, K; Sonohara, F; Yamada, S; Fujii, T; Han, IW; Tsai, SS; Kodera, Y; Park, JO; Von Hoff, D; Kim, SC; Li, W; Goel, A
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.01604 Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer Kindler, HL; Hammel, P; Reni, M; Van Cutsem, E; Macarulla, T; Hall, MJ; Park, JO; Hochhauser, D; Arnold, D; Oh, DY; Reinacher-Schick, A; Tortora, G; Algul, H; O'Reilly, EM; Bordia, S; McGuinness, D; Cui, KR; Locker, GY; Golan, T
    View PubMed
  • PATHOL ONCOL RES 2022 10.3389/pore.2022.1610697 MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer Ko, J; Jung, J; Kim, ST; Hong, JY; Park, S; Park, JO; Park, YS; Lim, HY; Ahn, S; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.22.00145 Light-to-Moderate Alcohol Consumption Increases the Risk of Biliary Tract Cancer in Prediabetes and Diabetes, but Not in Normoglycemic Status: A Nationwide Cohort Study Park, JH; Hong, JY; Han, K; Park, YS; Park, JO
    View PubMed
  • CANCERS 2022 10.3390/cancers14194556 The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer Shin, H; Yu, JI; Park, HC; Yoo, GS; Cho, S; Park, JO; Lee, KT; Lee, KH; Lee, JK; Park, JK; Heo, JS; Han, IW; Shin, SH
    View PubMed
  • HEPATOLOGY 2022 10.1002/hep.32804 Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study Borad, MJ; Bai, LY; Richards, D; Mody, K; Hubbard, J; Rha, SY; Soong, J; McCormick, D; Tse, E; O'Brien, D; Bayat, A; Ahn, D; Davis, SL; Park, JO; Oh, DY
    View PubMed
  • GASTROENTEROLOGY 2022 10.1053/j.gastro.2022.06.090 An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study Nakamura, K; Zhu, ZX; Roy, S; Jun, E; Han, HY; Munoz, RM; Nishiwada, S; Sharma, G; Cridebring, D; Zenhausern, F; Kim, S; Roe, DJ; Darabi, S; Han, IW; Evans, DB; Yamada, S; Demeure, MJ; Becerra, C; Celinski, SA; Borazanci, E; Tsai, S; Kodera, Y; Park, JO; Bolton, JS; Wang, X; Kim, SC; Von Hoff, D; Goel, A
    View PubMed
  • THER ADV GASTROENTER 2022 10.1177/17562848221117638 Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer Kim, H; Kim, R; Jo, H; Kim, HR; Hong, J; Ha, SY; Park, JO; Kim, ST
    View PubMed
  • CLIN ONCOL-UK 2022 10.1016/j.clon.2022.02.011 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer Jo, H; Lee, MS; Lee, YP; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11592-3 Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative-Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • ANN SURG ONCOL 2022 10.1245/s10434-022-11688-w ASO Visual Abstract: Determining Which Patients Require Preoperative Pelvic Radiotherapy Before Curative Intent Surgery and/or Ablation for Metastatic Rectal Cancer Yu, JI; Yoo, GS; Park, HC; Choi, DH; Lee, WY; Yun, SH; Kim, HC; Cho, YB; Huh, JW; Park, YA; Shin, JK; Park, JO; Kim, ST; Park, YS; Lee, J; Kang, WK; Lim, HY; Hong, JY
    View PubMed
  • J ONCOL 2022 10.1155/2022/9714570 Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing Hyung, S; Han, B; Jung, J; Kim, ST; Hong, JY; Park, SH; Zang, DY; Park, JO; Park, YS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • CANCER DISCOV 2022 10.1158/2159-8290.CD-21-0697 Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study Meric-Bernstam, F; Bahleda, R; Hierro, C; Sanson, M; Bridgewater, J; Arkenau, HT; Tran, B; Kelley, RK; Park, JO; Javle, M; He, YH; Benhadji, KA; Goyal, L
    View PubMed
  • GASTROENTEROLOGY 2022 10.1053/j.gastro.2021.09.070 Changes in Metabolic Syndrome Status are Associated With Altered Risk of Pancreatic Cancer: A Nationwide Cohort Study Park, JH; Han, K; Hong, JY; Park, YS; Hur, KY; Kang, G; Park, JO
    View PubMed
  • EUR J CANCER 2022 10.1016/j.ejca.2021.12.027 Association between alcohol consumption and pancreatic cancer risk differs by glycaemic status: A nationwide cohort study Park, JH; Han, K; Hong, JY; Park, YS; Park, JO
    View PubMed
  • MOL CANCER 2022 10.1186/s12943-021-01483-8 A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology Lee, IS; Zhu, ZX; Lee, J; Park, JO; Wu, XW; Ong, T; Li, SM; Wang, X; Chao, J; Goel, A
    View PubMed
  • TECHNOL CANCER RES T 2021 10.1177/15330338211062324 Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer Kim, H; Kim, H; Kim, R; Jo, H; Kim, HR; Hong, J; Park, JO; Park, YS; Kim, ST
    View PubMed
  • CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-0251 Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer Kim, ST; Smith, SA; Mortimer, P; Loembe, AB; Cho, H; Kim, KM; Smith, C; Willis, S; Irurzun-Arana, I; Berges, A; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kozarewa, I; Pierce, AJ; Dean, E; Lee, J
    View PubMed
  • J CANCER RES CLIN 2021 10.1007/s00432-021-03781-6 The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors Kim, H; Ahn, S; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • METABOLISM 2021 10.1016/j.metabol.2021.154848 Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study Park, JH; Hong, JY; Park, YS; Kang, G; Han, K; Park, JO
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.07.045 Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14) Kim, K; Il Yu, J; Jung, W; Kim, TH; Seong, J; Kim, WC; Choi, JH; Park, Y; Jeong, BK; Kim, BH; Kim, TG; Kim, JH; Park, HJ; Shin, HS; Im, JH; Heo, JS; Park, JO; Jang, JY; Oh, DY; Woo, SM; Lee, WJ; Chie, EK
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/17588359211038478 Comprehensive molecular profiling to predict clinical outcomes in pancreatic cancer Hong, JY; Cho, HJ; Kim, ST; Park, YS; Shin, SH; Han, IW; Lee, JY; Heo, JS; Park, JO
    View PubMed
  • EUR J CANCER 2021 10.1016/j.ejca.2021.06.052 Persistent status of metabolic syndrome and risk of cholangiocarcinoma: A Korean nationwide population- based cohort study Park, JH; Hong, JY; Park, YS; Kang, GS; Han, K; Park, JO
    View PubMed
  • J HEPATO-BIL-PAN SCI 2021 10.1002/jhbp.986 Multi-biomarker panel prediction model for diagnosis of pancreatic cancer Lee1, DH; Yoon, W; Lee, A; Han, Y; Byun, Y; Kang, JS; Kim, H; Kwon, W; Suh, YA; Choi, Y; Namkung, J; Han, S; Yi, SG; Heo, JS; Han, IW; Park, JO; Park, JK; Kim, SC; Jun, E; Kang, CM; Lee, WJ; Lee, HK; Lee, H; Lee, S; Jeong, SY; Lee, KE; Han, W; Park, T; Jang, JY
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100049 Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.02232 Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA) Hecht1, JR; Lonardi, S; Bendell, J; Sim, HW; Macarulla, T; Lopez, CD; Van Cutsem, E; Martin, AJM; Park, JO; Greil, R; Wang, H; Hozak, RR; Gueorguieva, I; Lin, Y; Rao, S; Ryoo, BY
    View PubMed
  • CANCERS 2021 10.3390/cancers13071647 Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review Yoo1, C; Shin, SH; Park, JO; Kim, KP; Jeong, JH; Ryoo, BY; Lee, W; Song, KB; Hwang, DW; Park, JH; Lee, JH
    View PubMed
  • ANN ONCOL 2021 10.1016/j.annonc.2020.11.017 A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
    View PubMed
  • ANN SURG TREAT RES 2021 10.4174/astr.2021.100.3.144 Diagnostic model for pancreatic cancer using a multi-biomarker panel Choi1, YJ; Yoon, W; Lee, A; Han, Y; Byun, Y; Kang, JS; Kim, H; Kwon, W; Suh, YA; Kim, Y; Lee, S; Namkung, J; Han, S; Choi, Y; Heo, JS; Park, JO; Park, JK; Kim, SC; Kang, CM; Lee, WJ; Park, T; Jang, JY
    View PubMed
  • ONCOLOGY-BASEL 2021 10.1159/000514404 Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2021 10.1177/1758835921992992 Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
    View PubMed
  • IN VIVO 2021 10.21873/invivo.12284 ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
    View PubMed
  • J CANCER 2021 10.7150/jca.49176 Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920965842 Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2020.218 A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer Kim1, JH; Kim, SY; Baek, JY; Cha, YJ; Ahn, JB; Kim, HS; Lee, KW; Kim, JW; Kim, TY; Chang, WJ; Park, JO; Kim, J; Kim, JE; Hong, YS; Kim, YH; Kim, TW
    View PubMed
  • GENOME MED 2020 10.1186/s13073-020-00776-9 Single-cell transcriptome analysis of tumor and stromal compartments of pancreatic ductal adenocarcinoma primary tumors and metastatic lesions Lin1, W; Noel, P; Borazanci, EH; Lee, J; Amini, A; Han, IW; Heo, JS; Jameson, GS; Fraser, C; Steinbach, M; Woo, Y; Fong, Y; Cridebring, D; Von Hoff, DD; Park, JO; Han, HY
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.20.00590 Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma Van Cutsem1, E; Tempero, MA; Sigal, D; Oh, DY; Fazio, N; Macarulla, T; Hitre, E; Hammel, P; Hendifar, AE; Bates, SE; Li, CP; Hingorani, SR; de la Fouchardiere, C; Kasi, A; Heinemann, V; Maraveyas, A; Bahary, N; Layos, L; Sahai, V; Zheng, L; Lacy, J; Park, JO; Portales, F; Oberstein, P; Wu, W; Chondros, D; Bullock, AJ
    View PubMed
  • EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855 Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
    View PubMed
  • NAT MED 2020 10.1038/s41591-020-0880-x BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial Bockorny1, B; Semenisty, V; Macarulla, T; Borazanci, E; Wolpin, BM; Stemmer, SM; Golan, T; Geva, R; Borad, MJ; Pedersen, KS; Park, JO; Ramirez, RA; Abad, DG; Feliu, J; Munoz, A; Ponz-Sarvise, M; Peled, A; Lustig, TM; Bohana-Kashtan, O; Shaw, SM; Sorani, E; Chaney, M; Kadosh, S; Haras, AV; Von Hoff, DD; Hidalgo, M
    View PubMed
  • THER ADV MED ONCOL 2020 10.1177/1758835920926796 First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
    View PubMed
  • Transl Cancer Res 2020 10.21037/tcr-19-1876 Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
    View PubMed
  • J CLIN ONCOL 2020 10.1200/JCO.19.01890 Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial Golan1, T; Kindler, HL; Park, JO; Reni, M; Macarulla, T; Hammel, P; Van Cutsem, E; Arnold, D; Hochhauser, D; McGuinness, D; Locker, GY; Goranova, T; Schatz, P; Liu, YZ; Hall, MJ
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-020-00706-0 Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CANCER RES TREAT 2020 10.4143/crt.2019.261 Carcinoembryonic Antigen Improves the Performance of Magnetic Resonance Imaging in the Prediction of Pathologic Response after Neoadjuvant Chemoradiation for Patients with Rectal Cancer Yoo1, GS; Park, HC; Yu, JI; Choi, DH; Cho, WK; Park, YS; Park, JO; Lim, HY; Kang, WK; Lee, WY; Kim, HC; Yun, SH; Cho, YB; Park, YA; Song, KD; Kim, SH; Ha, SY
    View PubMed
  • PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820 TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
    View PubMed
  • TARGET ONCOL 2020 10.1007/s11523-019-00691-z Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • CANCER SCI 2020 10.1111/cas.14264 Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study Bang1, YJ; Li, CP; Lee, KH; Chiu, CF; Park, JO; Shan, YS; Kim, JS; Chen, JS; Shim, HJ; Rau, KM; Choi, HJ; Oh, DY; Belanger, B; Chen, LT
    View PubMed
  • Genome Med 2020 10.1186/s13073-020-0717-8 Comprehensive pharmacogenomic characterization of gastric cancer Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
    View PubMed
  • J ONCOL 2020 10.1155/2020/4659062 Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
    View PubMed
  • CANCER SCI 2019 10.1111/cas.14264 Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study Bang1, YJ; Li, CP; Lee, KH; Chiu, CF; Park, JO; Shan, YS; Kim, JS; Chen, JS; Shim, HJ; Rau, KM; Choi, HJ; Oh, DY; Belanger, B; Chen, LT
    View PubMed
  • INT J CANCER 2019 10.1002/ijc.32228 Bridging genomics and phenomics of gastric carcinoma Cho1, J; Ahn, S; Son, DS; Kim, NKD; Lee, KW; Kim, S; Lee, J; Park, SH; Park, JO; Kang, WK; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, KM
    View PubMed
  • J CLIN ONCOL 2019 10.1200/JCO.19.00016 Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial Hong1, YS; Kim, SY; Lee, JS; Nam, BH; Kim, KP; Kim, JE; Park, YS; Park, JO; Baek, JY; Kim, TY; Lee, KW; Ahn, JB; Lim, SB; Yu, CS; Kim, JC; Yun, SH; Kim, JH; Park, JH; Park, HC; Jung, KH; Kim, TW
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2019.07.017 Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study Kwon1, D; Kim, B; Shin, HC; Kim, EJ; Ha, SY; Jang, KT; Kim, ST; Lee, J; Kang, WK; Park, JO; Kim, KM
    View PubMed
  • Front Oncol 2019 10.3389/fonc.2019.01327 Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening Lim1, SH; Sa, JK; Lee, DW; Kim, J; Kim, ST; Park, SH; Ku, B; Park, JO; Park, YS; Lim, H; Kang, WK; Nam, DH; Lee, J
    View PubMed
  • J Cancer 2019 10.7150/jca.37610 Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial Kim1, ST; Oh, SY; Lee, J; Kang, JH; Lee, HW; Lee, MA; Sohn, BS; Hong, JH; Park, YS; Park, JO; Lim, HY
    View PubMed
  • J IMMUNOTHER 2019 10.1097/CJI.0000000000000283 LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target Lee1, SJ; Byeon, SJ; Lee, J; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Kim, KM; Kim, ST
    View PubMed
  • CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442 Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
    View PubMed
  • SCI REP-UK 2019 10.1038/s41598-019-51981-5 Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients Bray1, SM; Lee, J; Kim, ST; Hur, JY; Ebert, PJ; Calley, JN; Wulur, IH; Gopalappa, T; Wong, SS; Qian, HR; Ting, JC; Liu, JG; Willard, MD; Novosiadly, RD; Park, YS; Park, JO; Lim, HY; Kang, WK; Aggarwal, A; Kim, HC; Reinhard, C
    View PubMed
  • ANTICANCER RES 2019 10.21873/anticanres.13785 Clinical Outcomes and the Role of Adjuvant Concurrent Chemoradiation Therapy in D2-resected LN-positive Young Patients (<= 45 Years) With Gastric Cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Lim, HY; Kim, ST; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • Transl Cancer Res 2019 10.21037/tcr.2019.09.27 Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs Cho1, JH; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • THER ADV MED ONCOL 2019 10.1177/1758835919871126 Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group Yoo1, C; Im, HS; Kim, KP; Oh, DY; Lee, KH; Chon, HJ; Kim, JH; Kang, M; Kim, I; Lee, GJ; Oh, SY; Choi, Y; Choi, HJ; Kim, ST; Park, JO; Ryoo, BY
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.401 Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols Yu1, JI; Lim, D; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Rae, JM; Yoo, H; Kim, K
    View PubMed
  • NEW ENGL J MED 2019 10.1056/NEJMoa1903387 Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer Golan1, T; Hammel, P; Reni, M; Van Cutsem, E; Macarulla, T; Hall, MJ; Park, JO; Hochhauser, D; Arnold, D; Oh, DY; Reinacher-Schick, A; Tortora, G; Algul, H; O'Reilly, EM; McGuinness, D; Cui, KY; Schlienger, K; Locker, GY; Kindler, HL
    View PubMed
  • Am J Transl Res 2019 Neutralizing antibody to FGFR2 can act as a selective biomarker and potential therapeutic agent for gastric cancer with FGFR2 amplification Kim1, ST; Lee, IK; Rom, E; Sirkis, R; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Yayon, A; Lee, J
    View PubMed
  • CANCER RES TREAT 2019 10.4143/crt.2018.379 A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients Kim1, Y; Kim, TW; Han, SW; Ahn, JB; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ANN ONCOL 2019 10.1093/annonc/mdz058 Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial Kim1, ST; Kang, JH; Lee, J; Lee, HW; Oh, SY; Jang, JS; Lee, MA; Sohn, BS; Yoon, SY; Choi, HJ; Hong, JH; Kim, MJ; Kim, S; Park, YS; Park, JO; Lim, HY
    View PubMed
  • ANN SURG 2019 10.1097/SLA.0000000000002582 Anastomotic Leak Does Not Impact Oncologic Outcomes After Preoperative Chemoradiotherapy and Resection for Rectal Cancer Jang1, JH; Kim, HC; Huh, JW; Park, YA; Cho, YB; Yun, SH; Lee, WY; Yu, JI; Park, HC; Park, YS; Park, JO
    View PubMed
  • PLoS One 2019 10.1371/journal.pone.0215080 Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
    View PubMed
  • TRANSL ONCOL 2019 10.1016/j.tranon.2018.12.009 Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial Kim1, ST; Lee, S; Park, M; Park, SH; Park, JO; Lim, HY; Park, YS; Kang, WK; Gangolli, EA; Shin, H; Kim, KM; Hollingsworth, SJ; Mortimer, PGS; Lee, J
    View PubMed
  • SURGERY 2019 10.1016/j.surg.2018.08.026 Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy Huh1, JW; Kim, HC; Kim, SH; Park, YA; Cho, YB; Yun, SH; Lee, WY; Park, HC; Choi, DH; Park, JO; Park, YS; Chun, HK
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • OncoTargets and therapy 2019 10.2147/OTT.S187621 The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • EUR J CANCER 2019 10.1016/j.ejca.2018.10.004 TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial) Ioka1, T; Ueno, M; Ueno, H; Park, JO; Chang, HM; Sasahira, N; Kanai, M; Chung, IJ; Ikeda, M; Nakamori, S; Mizuno, N; Omuro, Y; Yamaguchi, T; Hara, H; Sugimori, K; Furuse, J; Maguchi, H; Furukawa, M; Fukuzawa, K; Kim, JS; Yukisawa, S; Takeuchi, M; Okusaka, T; Boku, N; Hyodo, I
    View PubMed
  • J Gastric Cancer 2018 10.5230/jgc.2018.18.e34 Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial Kim1, Y; Kim, KM; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Lee, SJ; Kim, ST; Lee, J; Park, JO; Park, YS; Lim, HY; Kang, WK; Park, SH
    View PubMed
  • BMC CANCER 2018 10.1186/s12885-018-4995-0 Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line Kim1, ST; Kim, SY; Lee, J; Kim, K; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO
    View PubMed
  • RADIOTHER ONCOL 2018 10.1016/j.radonc.2018.07.002 Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer Yu1, JI; Lim, DH; Lee, J; Kang, WK; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, SJ; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, HS; Ahn, S
    View PubMed
  • J GASTROINTEST SURG 2018 10.1007/s11605-018-3815-9 Prognostic Role of Carcinoembryonic Antigen Level after Preoperative Chemoradiotherapy in Patients with Rectal Cancer Huh1, JW; Yun, SH; Kim, SH; Park, YA; Cho, YB; Kim, HC; Lee, WY; Park, HC; Choi, DH; Park, JO; Park, YS; Chun, HK
    View PubMed
  • NAT GENET 2018 10.1038/s41588-018-0209-6 Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy Lee1, JK; Liu, ZQ; Sa, JK; Shin, S; Wang, JG; Bordyuh, M; Cho, H; Elliott, O; Chu, T; Choi, SW; Rosenbloom, DIS; Lee, IH; Shin, YJ; Kang, HJ; Kim, D; Kim, SY; Sim, MH; Kim, J; Lee, T; Seo, YJ; Shin, H; Lee, M; Kim, SH; Kwon, YJ; Oh, JW; Song, M; Kim, M; Kong, DS; Choi, JW; Seol, HJ; Lee, JI; Kim, ST; Park, JO; Kim, KM; Song, SY; Lee, JW; Kim, HC; Lee, JE; Choi, MG; Seo, SW; Shim, YM; Zo, JI; Jeong, BC; Yoon, Y; Ryu, GH; Kim, NKD; Bae, JS; Park, WY; Lee, J; Verhaak, RGW; Iavarone, A; Lee, J; Rabadan, R; Nam, DH
    View PubMed
  • NAT MED 2018 10.1038/s41591-018-0101-z Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Kim1, ST; Cristescu, R; Bass, AJ; Kim, KM; Odegaard, JI; Kim, K; Liu, XQ; Sher, XW; Jung, H; Lee, M; Lee, S; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Choi, M; Talasaz, A; Kang, PS; Cheng, J; Loboda, A; Lee, J; Kang, WK
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.02.013 c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival Lee1, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • J Cancer 2018 10.7150/jca.26068 Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation Lee1, T; Kim, K; Lee, J; Park, SH; Park, YS; Lim, HY; Kang, WK; Park, JO; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.03.008 Final Analysis of Outcomes and RAS/BRAF Status in a Randomized Phase 3 Study of Panitumumab and Best Supportive Care in Chemorefractory Wild Type KRAS Metastatic Colorectal Cancer Kim1, TW; Elme, A; Park, JO; Udrea, AA; Kim, SY; Ahn, JB; Valencia, RV; Krishnan, S; Manojlovic, N; Guan, XS; Lofton-Day, C; Jung, AS; Vrdoljak, E
    View PubMed
  • ANN SURG 2018 10.1097/SLA.0000000000002705 Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial Jang1, JY; Han, Y; Lee, H; Kim, SW; Kwon, W; Lee, KH; Oh, DY; Chie, EK; Lee, JM; Heo, JS; Park, JO; Lim, DH; Kim, SH; Park, SJ; Lee, WJ; Koh, YH; Park, JS; Yoon, DS; Lee, LJ; Choi, SH
    View PubMed
  • CANCER RES TREAT 2018 10.4143/crt.2017.044 Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis Ji1, JH; Kim, YS; Park, I; Lee, SI; Kim, RB; Park, JO; Oh, SY; Hwang, IG; Jang, JS; Song, HN; Kang, JH
    View PubMed
  • BRIT J CANCER 2018 10.1038/s41416-018-0103-0 Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study Chau1, I; Park, JO; Ryoo, BY; Yen, CJ; Poon, R; Pastorelli, D; Blanc, JF; Kudo, M; Pfiffer, T; Hatano, E; Chung, HC; Kopeckova, K; Phelip, JM; Brandi, G; Ohkawa, S; Li, CP; Okusaka, T; Hsu, YZ; Abada, PB; Zhu, AX
    View PubMed
  • J Cancer 2018 10.7150/jca.24948 Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial Lim1, SW; Lee, S; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005 Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
    View PubMed
  • TRANSL ONCOL 2018 10.1016/j.tranon.2018.01.007 The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer Lee1, SJ; Kim, JE; Kim, ST; Lee, J; Park, SH; Park, JO; Kang, WK; Park, YS; Lim, HY
    View PubMed
  • J Cancer 2018 10.7150/jca.25132 The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer Kim1, ST; Kim, HK; Lee, J; Park, SH; Lim, HY; Park, YS; Kang, WK; Park, JO
    View PubMed
  • ANN ONCOL 2018 10.1093/annonc/mdy034 Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+gastric cancer patients Kim1, ST; Banks, KC; Pectasides, F; Kim, SY; Kim, K; Lanman, RB; Talasaz, A; An, J; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, NKD; Park, W; Lee, H; Bass, AJ; Kim, K; Kang, WK; Lee, J
    View PubMed
  • ONCOLOGIST 2018 10.1634/theoncologist.2017-0528 Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors Lee1, KW; Lee, DH; Kang, JH; Park, JO; Kim, SH; Hong, YS; Kim, ST; Oh, DY; Bang, YJ
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22511 Elevated CEA is associated with worse survival in recurrent rectal cancer Cho1, WK; Choi, DH; Park, HC; Park, W; Yu, JI; Park, YS; Park, JO; Lim, HY; Kang, WK; Kim, HC; Cho, YB; Yun, SH; Lee, WY
    View PubMed
  • INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • CLIN PHARMACOL THER 2017 10.1002/cpt.720 Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer Adiwijaya1, BS; Kim, J; Lang, I; Csoszi, T; Cubillo, A; Chen, JS; Wong, M; Park, JO; Kim, JS; Rau, KM; Melichar, B; Gallego, JB; Fitzgerald, J; Belanger, B; Molnar, I; Ma, WW
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.22394 MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines Kim1, JE; Kim, Y; Li, G; Kim, ST; Kim, K; Park, SH; Park, JO; Park, YS; Lim, HY; Lee, H; Sohn, TS; Kim, KM; Kang, WK; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.21861 Diagnostic performance enhancement of pancreatic cancer using proteomic multimarker panel Park1, J; Choi, Y; Namkung, J; Yi, SG; Kim, H; Yu, J; Kim, Y; Kwon, MS; Kwon, W; Oh, DY; Kim, SW; Jeong, SY; Han, W; Lee, KE; Heo, JS; Park, JO; Park, JK; Kim, SC; Kang, CM; Lee, WJ; Lee, S; Han, S; Park, T; Jang, JY; Kim, Y
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.3750 MerTK is a novel therapeutic target in gastric cancer Yi1, JH; Jang, J; Cho, J; Do, IG; Hong, M; Kim, ST; Kim, KM; Lee, S; Park, SH; Park, JO; Park, YS; Kang, WK; Lim, HY; Lee, J
    View PubMed
  • Oncoimmunology 2017 10.1080/2162402X.2017.1356150 Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity Park1, C; Cho, J; Lee, J; Kang, SY; An, JY; Choi, MG; Lee, JH; Sohn, TS; Bae, JM; Kim, S; Kim, ST; Park, SH; Park, JO; Kang, WK; Sohn, I; Jung, SH; Kang, MS; Kim, KM
    View PubMed
  • ONCOLOGIST 2017 10.1634/theoncologist.2017-0020 Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical Trials Kim1, ST; Kim, KM; Kim, NKD; Park, JO; Ahn, S; Yun, JW; Kim, KT; Park, SH; Park, PJ; Kim, HC; Sohn, TS; Il Choi, D; Cho, JH; Heo, JS; Kwon, W; Lee, H; Min, BH; Hong, SN; Park, YS; Lim, HY; Kang, WK; Park, WY; Lee, J
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.18168 The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs Kim1, HK; Ha, SY; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • ONCOTARGET 2017 10.18632/oncotarget.20492 Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy Kim1, ST; Klempner, SJ; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Lee, J
    View PubMed
  • J Cancer 2017 10.7150/jca.18286 The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer Kim1, ST; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS
    View PubMed
  • J Cancer 2017 10.7150/jca.19458 The Impact of Cetuximab Plus AKT- or mTOR-Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation Kim1, JS; Kim, JE; Kim, K; Lee, J; Park, JO; Lim, HY; Park, YS; Kang, WK; Kim, ST
    View PubMed
  • EUR J CANCER 2017 10.1016/j.ejca.2017.05.001 Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study Chau1, I; Peck-Radosavljevic, M; Borg, C; Malfertheiner, P; Seitz, JF; Park, JO; Ryoo, BY; Yen, CJ; Kudo, M; Poon, R; Pastorelli, D; Blanc, JF; Chung, HC; Baron, AD; Okusaka, T; Bowman, L; Cui, ZL; Girvan, AC; Abada, PB; Yang, L; Zhu, AX
    View PubMed
  • TUMORI 2017 10.5301/tj.5000666 Clinical outcomes of salvage chemoradiotherapy for locally recurrent biliary tract cancer Yu1, JI; Park, HC; Lim, DH; Park, JO; Park, YS; Kim, ST; Choi, SH; Choi, DW; Han, IW; Heo, JS
    View PubMed
  • EUR RADIOL 2017 10.1007/s00330-016-4644-4 Disappearing or residual tiny (ae<currency>5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Kim1, SS; Song, KD; Kim, YK; Kim, HC; Huh, JW; Park, YS; Park, JO; Kim, ST
    View PubMed
  • J Cancer 2017 10.7150/jca.19582 MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines Kim1, JE; Kim, KK; Kim, SY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
    View PubMed
  • Cancer Res Treat. 2017 Apr;49(2):350-357. doi: 10.4143/crt.2016.067. Epub 2016 Jul 19. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program Son MK11, Ryu MH1, Park JO2, Im SA3, Kim TY3, Lee SJ2, Ryoo BY1, Park SR1, Kang YK1.
    View PubMed
  • Ann Oncol. 2017 Mar 1;28(3):547-554. doi: 10.1093/annonc/mdw669. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition Kim ST11, Kim SY1, Klempner SJ2,3, Yoon J4, Kim N4, Ahn S4,5, Bang H5,6, Kim KM5,6, Park W4, Park SH1, Park JO1, Park YS1, Lim HY1, Lee SH1, Park K1,6, Kang WK1, Lee J1.
    View PubMed
  • BMC Cancer. 2017 Mar 23;17(1):211. doi: 10.1186/s12885-017-3196-6. Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy Kim ST11, Lee J1, Park SH1, Park JO1, Park YS1, Kang WK1, Lim HY2.
    View PubMed
  • JAMA Oncol. 2016 Sep 22. doi: 10.1001/jamaoncol.2016.4115. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh Score Zhu AX11, Baron AD2, Malfertheiner P3, Kudo M4, Kawazoe S5, Pezet D6, Weissinger F7, Brandi G8, Barone CA9, Okusaka T10, Wada Y11, Park JO12, Ryoo BY13, Cho JY14, Chung HC15, Li CP16, Yen CJ17, Lee KD18, Chang SC19, Yang L20, Abada PB21, Chau I22.
    View PubMed
  • Oncotarget. 2017 Feb 14;8(7):11094-11104. doi: 10.18632/oncotarget.14362. Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer Kim JH11, Lee SH2, Choi S2, Kim U3, Yeo IS4, Kim SH2, Oh MJ3, Moon H3, Lee J3, Jeong S3, Choi MG5, Lee JH5, Sohn TS5, Bae JM5, Kim S5, Min YW5, Lee H5, Lee JH5, Rhee PL5, Kim JJ5, Lee SJ5, Kim ST5, Lee J5, Park SH5, Park JO5, Park YS5, Lim HY5, Kang WK5, An HJ3, Kim JH4.
    View PubMed
  • Oncotarget. 2017 Jan 10;8(2):3237-3245. doi: 10.18632/oncotarget.13700. The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors Lim SH11, Kim SY1, Kim K2, Jang H1, Ahn S2, Kim KM2, Kim NK3, Park W3, Lee SJ1, Kim ST1, Park SH1, Park JO1, Park YS1, Lee SH1, Lim HY1, Park K1, Kang WK1, Lee J1.
    View PubMed
  • Mol Cancer Ther. 2017 Jan;16(1):228-238. doi: 10.1158/1535-7163.MCT-15-0887. Epub 2016 Nov 3. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-O13/LOGiC Trial of Lapatinib Press MF11, Ellis CE2, Gagnon RC3, Grob TJ4, Buyse M5, Villalobos I6, Liang Z7, Wu S7, Bang YJ8, Qin SK9, Chung HC10, Xu J11, Park JO12, Jeziorski K13, Afenjar K14, Ma Y6, Estrada MC6, Robinson DM15, Scherer SJ15, Sauter G4, Hecht JR16, Slamon DJ16.
    View PubMed
  • Oncotarget. 2016 Nov 15;7(46):75482-75491. doi: 10.18632/oncotarget.12780. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis Park JO11, Ryoo BY2, Yen CJ3, Kudo M4, Yang L5, Abada PB6, Cheng R7, Orlando M8, Zhu AX9, Okusaka T10.
    View PubMed
  • Br J Cancer. 2016 Nov 8;115(10):1206-1214. doi: 10.1038/bjc.2016.309. Epub 2016 Oct 13. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer Kim TW11, Elme A2, Kusic Z3, Park JO4, Udrea AA5, Kim SY6, Ahn JB7, Valencia RV8, Krishnan S9, Bilic A10, Manojlovic N11, Dong J12, Guan X12, Lofton-Day C12, Jung AS12, Vrdoljak E13.
    View PubMed
  • J Cancer. 2016 Oct 25;7(15):2173-2178. eCollection 2016. To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients Lee H11, Lee J2, Sohn I3, Park SH2, Park JO2, Park YS2, Kim KM4, Kang WK2, Kim ST2.
    View PubMed
  • CANCER RESEARCH AND TREATMENT, OCT 2016, 48(4) :1274-1285, DOI: 10.4143/crt.2015.502 Is There a Role for Adjuvant Therapy in RO Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis Go SI1, Kim YS, Hwang IG, Kim EY, Oh SY, Ji JH, Song HN, Park SH, Park JO, Kang JH
    View PubMed
  • Oncotarget. 2016 Sep 20;7(38):62676-62686. doi: 10.18632/oncotarget.10445. Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy Yu JI11, Lee H2, Park HC1, Choi DH1, Choi YL3, Do IG4, Kim HC5, Lee WY5, Yun SH5, Cho YB5, Huh JW5, Park YA6, Park YS6, Park JO6, Kim ST6, Park W1.
    View PubMed
  • Oncotarget. 2016 Jul 12;7(28):43492-43503. doi: 10.18632/oncotarget.9523. MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis Lee JY11, Lee I2, Chang WJ3, Ahn SM4,5, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Cho JH1, Kim SY1, Kim KM4,5, Lee S1, Kim ST1, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, JUL 2016, 43(8):1461-1468, DOI: 10.1007/s00259-016-3316-6 Intratumoral heterogeneity of F-18-FDG uptake predicts survival in patients with pancreatic ductal adenocarcinoma Hyun SH1, Kim HS, Choi SH, Choi DW, Lee JK, Lee KH, Park JO, Lee KH, Kim BT, Choi JY
    View PubMed
  • Transl Oncol. 2016 Jun;9(3):173-8. doi: 10.1016/j.tranon.2016.01.007. Epub 2016 Apr 22. Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing Yoo KH11, Kim NK2, Kwon WI3, Lee C2, Kim SY1, Jang J1, Ahn J1, Kang M1, Jang H1, Kim ST1, Ahn S4, Jang KT4, Park YS1, Park WY5, Lee J6, Heo JS7, Park JO8.
    View PubMed
  • J Cancer Res Clin Oncol. 2016 Jun;142(6):1231-7. doi: 10.1007/s00432-016-2143-2. Epub 2016 Mar 16. Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin) Kim ST11, Ahn S2, Lee J1, Lee SJ1, Park SH1, Park YS1, Lim HY1, Kang WK1, Kim KM2, Park JO3.
    View PubMed
  • J Cancer. 2016 May 25;7(9):1044-8. doi: 10.7150/jca.14815. eCollection 2016. Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era Kim ST11, Lee SJ1, Park SH1, Park JO1, Lim HY1, Kang WK1, Lee J1, Park YS1.
    View PubMed
  • Cancer Chemother Pharmacol. 2016 May;77(5):979-85. doi: 10.1007/s00280-016-3014-x. Epub 2016 Mar 26. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma Kim YS11, Hwang IG2, Park SE3, Go SI4, Kang JH4, Park I1, Oh SY5, Ji JH6, Song HN7, Park SH7, Kim ST7, Park JO7.
    View PubMed
  • Oncotarget. 2016 Apr 12;7(15):19610-9. doi: 10.18632/oncotarget.7526. Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment Song HN11,2, Lee C3,4, Kim ST1, Kim SY1, Kim NK3, Jang J1, Kang M1, Jang H1, Ahn S5, Kim SH5, Park Y6, Cho YB6, Heo JW6, Lee WY6, Park JO1, Lim HY1, Kang WK1, Park YS1, Park WY3,7,4, Lee J1, Kim HC6.
    View PubMed
  • Oncotarget. 2016 Apr 26;7(17):24088-96. doi: 10.18632/oncotarget.8175. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer Kim ST11, Lee J1, Lee SJ1, Park SH1, Jung SH2, Park YS1, Lim HY1, Kang WK1, Park JO1.
    View PubMed
  • Cancer Res Treat. 2016 Apr;48(2):553-60. doi: 10.4143/crt.2015.155. Epub 2015 Aug 10. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology Yi JH11, Kang JH2, Hwang IG3, Ahn HK4, Baek HJ5, Lee SI5, Lim DH5, Won YW6, Ji JH7, Kim HS8, Rha SY8, Oh SY9, Lee KE10, Lim T11, Maeng CH12, Kim MJ13, Kim ST13, Lee J13, Park JO13, Park YS13, Lim HY13, Kang WK13, Park SH13.
    View PubMed
  • Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation Kim N11,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.
    View PubMed
  • Oncotarget. 2016 Feb 9;7(6):6538-51. doi: 10.18632/oncotarget.3731. Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors Kang G11,2, Yun H1,3, Sun CH3, Park I3, Lee S3, Kwon J3, Do I1,4,5, Hong ME1,5,6, Van Vrancken M1, Lee J7, Park JO7, Cho J8, Kim KM1,5, Sohn TS9.
    View PubMed
  • J Cancer. 2016 Feb 5;7(5):484-9. doi: 10.7150/jca.13711. eCollection 2016. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs Kim ST11, Ha SY2, Lee S1, Ahn S2, Lee J1, Park SH1, Park JO1, Lim HY1, Kang WK1, Kim KM2, Park YS1.
    View PubMed
  • BMC Cancer. 2016 Feb 18;16:120. doi: 10.1186/s12885-016-2141-4. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis Kim HS11,2, Heo JS3, Lee J4, Lee JY5, Lee MY6, Lim SH7, Lee WY8, Kim SH9, Park YA10, Cho YB11, Yun SH12, Kim ST13, Park JO14, Lim HY15, Choi YS16, Kwon WI17, Kim HC18, Park YS19.
    View PubMed
  • J Clin Oncol. 2016 Feb 10;34(5):443-51. doi: 10.1200/JCO.2015.62.6598. Epub 2015 Nov 30. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial Hecht JR11, Bang YJ2, Qin SK2, Chung HC2, Xu JM2, Park JO2, Jeziorski K2, Shparyk Y2, Hoff PM2, Sobrero A2, Salman P2, Li J2, Protsenko SA2, Wainberg ZA2, Buyse M2, Afenjar K2, Houe V2, Garcia A2, Kaneko T2, Huang Y2, Khan-Wasti S2, Santillana S2, Press MF2, Slamon D2.
    View PubMed
  • Cancer Res Treat. 2016 Jan;48(1):153-61. doi: 10.4143/crt.2014.183. Epub 2015 Mar 7. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors Kim M11, Lee S2, Lee J2, Park SH2, Park JO2, Park YS2, Kang WK2, Kim ST2.
    View PubMed
  • Medicine (Baltimore). 2016 Jan;95(3):e2582. doi: 10.1097/MD.0000000000002582. Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation Huh JW11, Kim HC, Kim SH, Park YA, Cho YB, Yun SH, Lee WY, Park HC, Choi DH, Park JO, Park YS, Chun HK.
    View PubMed
  • Tumori. 2016 Jan-Feb;102(1):114-21. doi: 10.5301/tj.5000439. Epub 2015 Oct 7. Clinical significance of mucinous rectal adenocarcinoma following preoperative chemoradiotherapy and curative surgery Kim TG11, Park W2, Choi DH2, Park HC2, Kim SH3, Cho YB4, Yun SH4, Kim HC4, Lee WY4, Lee J5, Park JO5, Park YS5, Lim HY5, Kang WK5, Chun HK6.
    View PubMed
  • Br J Cancer. 2015 Nov 17;113(10):1421-6. doi: 10.1038/bjc.2015.371. Epub 2015 Oct 27. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer Lim SH11, Kim TW2, Hong YS2, Han SW3, Lee KH3, Kang HJ4, Hwang IG5, Lee JY1, Kim HS1, Kim ST1, Lee J1, Park JO1, Park SH1, Park YS1, Lim HY1, Jung SH6,7, Kang WK1.
    View PubMed
  • J Clin Oncol. 2015 Nov 20;33(33):3858-65. doi: 10.1200/JCO.2014.60.0320. Epub 2015 Aug 17. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Bang YJ11, Im SA2, Lee KW2, Cho JY2, Song EK2, Lee KH2, Kim YH2, Park JO2, Chun HG2, Zang DY2, Fielding A2, Rowbottom J2, Hodgson D2, O'Connor MJ2, Yin X2, Kim WH2.
    View PubMed
  • Oncotarget. 2015 Nov 17;6(36):39028-35. doi: 10.18632/oncotarget.5494. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line Lee SJ11, Li GG2, Kim ST1, Hong ME3, Jang J1, Yoon N3, Ahn SM3, Murphy D2, Christiansen J2, Wei G2, Hornby Z2, Lee DW4, Park JO1,5, Park YS1, Lim HY1, Hong SN6, Kim SH3, Kang WK1, Park K1, Park WY7, Kim KM3,5, Lee J1.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40360-9. doi: 10.18632/oncotarget.5465. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients Kim ST11, Lee WS2, Lanman RB3, Mortimer S3, Zill OA3, Kim KM4,5, Jang KT5, Kim SH5, Park SH1, Park JO1,4, Park YS1, Lim HY1, Eltoukhy H3, Kang WK1, Lee WY6, Kim HC6, Park K1,4, Lee J1,4, Talasaz A3.
    View PubMed
  • Oncotarget. 2015 Nov 24;6(37):40026-35. doi: 10.18632/oncotarget.5432. PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA Kim ST11, Lira M2, Deng S2, Lee S1, Park YS1, Lim HY1, Kang WK1, Mao M3, Heo JS4, Kwon W4, Jang KT5, Lee J1,6, Park JO1,6.
    View PubMed
  • J Clin Oncol. 2015 Oct 1;33(28):3130-6. doi: 10.1200/JCO.2014.58.3930. Epub 2015 Jan 5. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses Park SH11, Sohn TS1, Lee J1, Lim DH1, Hong ME1, Kim KM1, Sohn I1, Jung SH1, Choi MG1, Lee JH1, Bae JM1, Kim S1, Kim ST1, Park JO1, Park YS1, Lim HY1, Kang WK2.
    View PubMed
  • Int J Biol Markers. 2015 Nov 11;30(4):e382-6. doi: 10.5301/jbm.5000151. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer Lee SJ11, Lee J1, Kim ST1, Park SH1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Radiother Oncol. 2015 Oct;117(1):171-7. doi: 10.1016/j.radonc.2015.08.009. Epub 2015 Aug 20. Effects of adjuvant radiotherapy on completely resected gastric cancer: A radiation oncologist's view of the ARTIST randomized phase III trial Yu JI11, Lim do H2, Ahn YC1, Lee J3, Kang WK3, Park SH3, Park JO3, Park YS3, Lim HY3, Kim ST3, Kim S4, Sohn TS4, Choi MG4, Bae JM4, Nam H5.
    View PubMed
  • BMC Cancer. 2015 Oct 20;15:747. doi: 10.1186/s12885-015-1759-y. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan Kim ST1, Ahn TJ, Lee E, Do IG, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim SH, Lee J, Kim HC
    View PubMed
  • Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
    View PubMed
  • Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721. Gastrointestinal malignancies harbor actionable MET exon 14 deletions Lee J11,2, Ou SH3, Lee JM4, Kim HC5, Hong M6, Kim SY1, Jang J1, Ahn S6, Kang SY6, Lee S1, Kim ST1, Kim B4, Choi J4, Kim KA4, Lee J1, Park C1,6, Park SH1, Park JO1,2, Lim HY1, Kang WK1, Park K1,2, Park YS1, Kim KM2,6.
    View PubMed
  • Oncotarget. 2015 Sep 15;6(27):24320-32. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening Lee J11, Kim HC2, Hong JY3, Wang K4, Kim SY1, Jang J1, Kim ST1, Park JO1, Lim HY1, Kang WK1, Park YS1, Lee J1, Lee WY2, Park YA2, Huh JW2, Yun SH2, Do IG5, Kim SH5, Balasubramanian S4, Stephens PJ4, Ross JS4,6, Li GG7, Hornby Z7, Ali SM4, Miller VA4, Kim KM5,8, Ou SH9.
    View PubMed
  • Mol Ther. 2015 Sep;23(9):1532-40. doi: 10.1038/mt.2015.109. Epub 2015 Jun 15. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Park SH11, Breitbach CJ2, Lee J1, Park JO1, Lim HY1, Kang WK1, Moon A2,3, Mun JH4, Sommermann EM4, Maruri Avidal L4, Patt R5, Pelusio A2, Burke J2, Hwang TH4,6, Kirn D2, Park YS1.
    View PubMed
  • Oncotarget. 2015 Sep 22;6(28):25619-30. doi: 10.18632/oncotarget.4627. Patient-derived cell models as preclinical tools for genome-directed targeted therapy Lee JY11, Kim SY1, Park C1, Kim NK2, Jang J1, Park K2, Yi JH3, Hong M4,5, Ahn T2, Rath O6, Schueler J6, Kim ST1, Do IG5, Lee S1, Park SH1, Ji YI7, Kim D7, Park JO1,4, Park YS1, Kang WK1, Kim KM4,5, Park WY2,7, Lim HY1, Lee J1,4.
    View PubMed
  • Transl Oncol. 2015 Aug;8(4):288-94. doi: 10.1016/j.tranon.2015.06.001. Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer Kim ST11, Jang HL2, Lee J1, Park SH1, Park YS1, Lim HY1, Choi MG3, Bae JM3, Sohn TS3, Noh JH3, Kim S3, Kim KM4, Kang WK1, Park JO5.
    View PubMed
  • BMC Cancer. 2015 Jul 21;15:530. doi: 10.1186/s12885-015-1552-y. Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer Kim ST11, Jang KT2, Lee SJ3, Jang HL4, Lee J5, Park SH6, Park YS7, Lim HY8, Kang WK9, Park JO10.
    View PubMed
  • Cancer Res Treat. 2015 Jul;47(3):343-61. doi: 10.4143/crt.2014.308. Epub 2015 May 18. Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review Park JO11, Oh DY2, Hsu C3, Chen JS4, Chen LT5, Orlando M6, Kim JS7, Lim HY1.
    View PubMed
  • Lancet Oncol. 2015 Jul;16(7):859-70. doi: 10.1016/S1470-2045(15)00050-9. Epub 2015 Jun 18. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial Zhu AX1, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators.
    View PubMed
  • Oncology. 2015;89(1):14-22. doi: 10.1159/000371390. Epub 2015 Mar 11. Is Chemoradiotherapy Beneficial for Stage IV Rectal Cancer Huh JW11, Kim HC, Park HC, Choi DH, Park JO, Park YS, Park YA, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Int J Cancer. 2015 Apr 1;136(7):1629-35. doi: 10.1002/ijc.29159. Epub 2014 Sep 4. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: A distinct subset of patients for dual inhibition therapy Ha SY11, Lee J, Jang J, Hong JY, Do IG, Park SH, Park JO, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Kang WK, Kim KM.
    View PubMed
  • Cancer Chemother Pharmacol. 2015 Apr;75(4):757-62. doi: 10.1007/s00280-015-2691-1. Epub 2015 Feb 13. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer Hwang IG11, Jang JS, Oh SY, Rho MH, Lee S, Park YS, Park JO, Nam EM, Lee HR, Jun HJ, Chi KC.
    View PubMed
  • Oncotarget. 2015 Apr 20;6(11):8839-50. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants Park AK11,2, Francis JM3, Park WY1,2, Park JO4, Cho J1,2.
    View PubMed
  • Ann Surg Oncol. 2015 Apr;22(4):1308-14. doi: 10.1245/s10434-014-4146-z. Epub 2014 Oct 16. Salvage Radiation Therapy for Isolated Local Recurrence of Extrahepatic Cholangiocarcinoma After Radical Surgery: A Retrospective Study Kim SW11, Lim do H, Park HC, Park W, Park JO, Park YS.
    View PubMed
  • Jpn J Clin Oncol. 2015 Mar;45(3):256-60. doi: 10.1093/jjco/hyu210. Epub 2015 Jan 26. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC) Ji JH11, Song HN2, Kim RB3, Oh SY4, Lim HY5, Park JO5, Park SH5, Kim MJ5, Lee SI6, Ryou SH6, Hwang IG7, Jang JS7, Kim HJ8, Choi JY9, Kang JH10.
    View PubMed
  • J Surg Oncol. 2015 Mar 15;111(4):439-44. doi: 10.1002/jso.23835. Epub 2014 Dec 9. Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Curative Resection for Rectal Cancer: Is it Necessary for all Patients Jung KU11, Kim HC, Park JO, Park YS, Park HC, Choi DH, Cho YB, Yun SH, Lee WY, Chun HK.
    View PubMed
  • Transl Oncol. 2015 Feb;8(1):40-6. doi: 10.1016/j.tranon.2014.12.003. Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer Kim ST11, Jang KT2, Lee J1, Jang HM3, Choi HJ4, Jang HL1, Park SH1, Park YS1, Lim HY1, Kang WK1, Park JO5.
    View PubMed
  • Cancer Res Treat. 2015 Jan;47(1):72-7. doi: 10.4143/crt.2013.172. Epub 2014 Aug 21. Changes in the Mean Corpuscular Volume after Capecitabine Treatment are Associated with Clinical Response and Survival in Patients with Advanced Gastric Cancer Jung HA11, Kim HJ2, Maeng CH3, Park SH1, Lee J1, Park JO1, Park YS1, Lim HY1, Kang WK1.
    View PubMed
  • Yonsei Med J. 2015 Jan;56(1):82-8. doi: 10.3349/ymj.2015.56.1.82. Immunohistochemical Detection of p53 Expression in Patients with Preoperative Chemoradiation for Rectal Cancer: Association with Prognosis Huh JW11, Lee WY2, Kim SH3, Park YA1, Cho YB1, Yun SH1, Kim HC1, Park HC4, Choi DH4, Park JO5, Park YS5, Chun HK6.
    View PubMed
  • Sci Rep. 2014 Dec 23;4:7592. doi: 10.1038/srep07592. Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer Yi JH11, Do IG2, Jang J3, Kim ST3, Kim KM4, Park SH3, Park JO3, Park YS3, Lim HY3, Kang WK3, Lee J3.
    View PubMed
  • Mol Cancer Ther. 2014 Nov;13(11):2527-36. doi: 10.1158/1535-7163.MCT-14-0255. Epub 2014 Sep 23. Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows Potent In Vitro Antitumor Activity in Gastric Cancer Cell Lines with FGFR2 Amplification Kim ST11, Jang HL2, Lee SJ1, Lee J1, Choi YL3, Kim KM3, Cho J4, Park SH1, Park YS1, Lim HY1, Yashiro M5, Kang WK1, Park JO6.
    View PubMed
  • Eur J Cancer. 2014 Nov;50(16):2822-30. doi: 10.1016/j.ejca.2014.08.005. Epub 2014 Sep 15. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: A double-blind randomised phase 3 study Kim ST11, Kang JH2, Lee J1, Park SH1, Park JO1, Park YS1, Lim HY1, Hwang IG3, Lee SC4, Park KW5, Lee HR6, Kang WK7.
    View PubMed
  • Nat Commun. 2014 Nov 19;5:5477. doi: 10.1038/ncomms6477. Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing Wong SS11, Kim KM2, Ting JC1, Yu K1, Fu J3, Liu S4, Cristescu R5, Nebozhyn M5, Gong L4, Yue YG1, Wang J1, Ronghua C5, Loboda A5, Hardwick J5, Liu X5, Dai H5, Jin JG3, Ye XS1, Kang SY2, Do IG2, Park JO6, Sohn TS7, Reinhard C1, Lee J6, Kim S7, Aggarwal A1.
    View PubMed
  • Anticancer Res. 2014 Nov;34(11):6585-91. Adjuvant Chemoradiation with 5-Fluorouracil/Leucovorin versus S-1 in Gastric Cancer Patients Following D2 Lymph Node Dissection Surgery: A Feasibility Study Lee SJ11, Sohn TS2, Lee J1, Park SH1, Park JO1, Lim DH3, Park YS1, Lim HY1, Choi MG4, Lee JH4, Bae JM4, Kim S4, Kang WK5.
    View PubMed
  • Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial Hong YS11, Nam BH2, Kim KP1, Kim JE1, Park SJ1, Park YS3, Park JO3, Kim SY4, Kim TY5, Kim JH6, Ahn JB7, Lim SB8, Yu CS8, Kim JC8, Yun SH9, Kim JH10, Park JH10, Park HC11, Jung KH1, Kim TW12.
    View PubMed
  • Cancer Genomics Proteomics. 2014 Sep-Oct;11(5):259-66. Transcriptome Analysis of CD133-positive Stem Cells and Prognostic Value of Survivin in Colorectal Cancer Kim ST11, Sohn I2, DO IG3, Jang J4, Kim SH3, Jung IH5, Park JO1, Park YS1, Talasaz A6, Lee J1, Kim HC7.
    View PubMed
  • Colorectal Dis. 2014 Aug;16(8):O257-63. doi: 10.1111/codi.12554. The adequacy of the distal resection margin after preoperative chemoradiotherapy for rectal cancer Kim TG11, Park W, Choi DH, Kim SH, Kim HC, Lee WY, Park JO, Park YS.
    View PubMed
  • Eur J Cancer. 2014 Aug;50(12):2072-81. doi: 10.1016/j.ejca.2014.04.024. Epub 2014 Jun 7. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Infante JR11, Somer BG2, Park JO3, Li CP4, Scheulen ME5, Kasubhai SM6, Oh DY7, Liu Y8, Redhu S8, Steplewski K8, Le N9.
    View PubMed
  • PLoS One. 2014 Aug 4;9(8):e103551. doi: 10.1371/journal.pone.0103551. eCollection 2014. Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status Lee J11, Jain A2, Kim P2, Lee T2, Kuller A2, Princen F2, In-GuDo3, Kim SH3, Park JO1, Park YS1, Singh S2, Kim HC4.
    View PubMed
  • Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10. Prognostic and predictive value of metabolic tumor volume on F-18-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib Choi MK111, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY.
    View PubMed
  • Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab Lee J11, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
    View PubMed
  • Ann Surg Oncol. 2014 Apr;21(4):1099-106. doi: 10.1245/s10434-013-3339-1. Epub 2013 Dec 4. CD151 Overexpression is Associated with Poor Prognosis in Patients with pT3 Gastric Cancer Ha SY11, Do IG, Lee J, Park SH, Park JO, Kang WK, Choi MG, Lee JH, Bae JM, Kim S, Kim KM, Sohn TS.
    View PubMed
  • PLoS One. 2014 Mar 5;9(3):e90133. doi: 10.1371/journal.pone.0090133. eCollection 2014. Nanostring-Based Multigene Assay to Predict Recurrence for Gastric Cancer Patients after Surgery Lee J11, Sohn I2, Do IG3, Kim KM4, Park SH1, Park JO1, Park YS1, Lim HY1, Sohn TS5, Bae JM5, Choi MG5, Lim DH6, Min BH7, Lee JH7, Rhee PL7, Kim JJ7, Choi DI8, Tan IB9, Das K10, Tan P11, Jung SH2, Kang WK1, Kim S5.
    View PubMed
  • Int J Colorectal Dis. 2014 Feb;29(2):193-200. doi: 10.1007/s00384-013-1797-3. Epub 2013 Dec 10. Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients Kim TG11, Park W, Choi DH, Park HC, Kim SH, Cho YB, Yun SH, Kim HC, Lee WY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Chun HK.
    View PubMed
  • Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. doi: 10.1007/s00280-013-2328-1. Epub 2013 Oct 27. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients Hong JY11, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS.
    View PubMed
  • Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Lordick F1, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, G?tte H, Melez?nkov? H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators.
    View PubMed
  • Am J Clin Oncol.?2012 Oct;35(5):432-8. Safety and Efficacy of Adjuvant Chemoradiation Therapy With Capecitabine After Resection of Pancreatic Ductal Adenocarcinoma A Retrospective Review Kim ST11,?Lee J,?Park SH,?Lee JK,?Lee KT,?Lee KH,?Heo JS,?Choi SH,?Choi DW,?Park YS,?Lim HY,?Kang WK,?Jang KT,?Park HC,?Lim do H,?Park JO.
    View PubMed
  • Pharmacogenomics. 2012 Jul;13(9):1023-35. doi: 10.2217/pgs.12.82. Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine Woo HI11, Kim KK, Choi H, Kim S, Jang KT, Yi JH, Park YS, Park JO, Lee SY.
    View PubMed
  • Nephrol Dial Transplant. 2012 Jan;27(1):218-25. doi: 10.1093/ndt/gfr267. Epub 2011 May 28. Uremia induces functional incompetence of bone marrow-derived stromal cells Noh H11, Yu MR, Kim HJ, Jeon JS, Kwon SH, Jin SY, Lee J, Jang J, Park JO, Ziyadeh F, Han DC, Lee HB.
    View PubMed
  • Mol?Cancer?Ther.?2011 Oct;10(10):1993-9. doi: 10.1158/1535-7163.MCT-11-0269. Epub 2011 Aug 23. Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy Kim ST11,?Lim do H,?Jang KT,?Lim T,?Lee J,?Choi YL,?Jang HL,?Yi JH,?Baek KK,?Park SH,?Park YS,?Lim HY,?Kang WK,?Park JO.
    View PubMed
  • Oncology. 2011;80(3-4):175-80. doi: 10.1159/000328449. Epub 2011 Jun 24. A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer Yi JH11, Lee J, Park SH, Lee KT, Lee JK, Lee KH, Choi DW, Choi SH, Heo JS, Lim do H, Park YS, Lim HY, Kang WK, Park K, Park JO.
    View PubMed
  • Oncology. 2011;80(3-4):257-61. doi: 10.1159/000328795. Epub 2011 Jul 6. High-Dose Ifosfamide as Second- or Third-Line Chemotherapy in Refractory Bone and Soft Tissue Sarcoma Patients Lee SH11, Chang MH, Baek KK, Han B, Lim T, Lee J, Park JO.
    View PubMed
  • Oncol Rep. 2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18. Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients Lee J11, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO.
    View PubMed
  • Oncol Rep.?2011 Jun;25(6):1517-24. doi: 10.3892/or.2011.1219. Epub 2011 Mar 18. Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target Lee J11,?Seo JW,?Jun HJ,?Ki CS,?Park SH,?Park YS,?Lim HY,?Choi MG,?Bae JM,?Sohn TS,?Noh JH,?Kim S,?Jang HL,?Kim JY,?Kim KM,?Kang WK,?Park JO.
    View PubMed
  • Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration Ahn BJ11, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS.
    View PubMed
  • Anticancer Drugs. 2010 Jan;21(1):107-12. doi: 10.1097/CAD.0b013e328332a7fc. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer Kim HS11, Yi SY, Jun HJ, Lee J, Park SH, Lee JK, Lee KT, Lee KH, Choi DW, Choi SH, Heo JS, Park YS, Lim HY, Kang WK, Park HC, Lim do H, Park JO.
    View PubMed
  • Cancer Lett. 2009 Sep 8;282(1):14-24. doi: 10.1016/j.canlet.2009.02.056. Epub 2009 Apr 3. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression Mukohara T11, Shimada H, Ogasawara N, Wanikawa R, Shimomura M, Nakatsura T, Ishii G, Park JO, J?nne PA, Saijo N, Minami H.
    View PubMed
  • Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor Ryu MH11, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.
    View PubMed
  • J Clin Oncol. 2007 Nov 20;25(33):5233-9. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non-small-cell lung cancer Park JO11, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K.
    View PubMed
  • Cancer Chemother Pharmacol. 2007 Sep;60(4):489-94. Epub 2007 Mar 30. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma Park BB11, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim do H, Park YS, Lim HY, Kang WK, Park K.
    View PubMed
  • J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma Park BK11, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.
    View PubMed
  • J Gastroenterol Hepatol. 2006 Jun;21(6):999-1003. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer Park BK11, Kim YJ, Park JY, Bang S, Park SW, Chung JB, Kim KS, Choi JS, Lee WJ, Song SY.
    View PubMed
  • Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. Epub 2005 Nov 5. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer Park SH11, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    View PubMed
  • Hepatocellular carcinoma with metastasis to the breast
  • Cancer Chemother Pharmacol.?2004 Nov;54(5):385-90. Epub 2004 Jul 10. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma Lee J11,?Park JO,?Kim WS,?Park SH,?Park KW,?Choi MS,?Lee JH,?Koh KC,?Paik SW,?Yoo BC,?Joh J,?Kim K,?Jung CW,?Park YS,?Im YH,?Kang WK,?Lee MH,?Park K.
    View PubMed
  • Oncology.?2004;66(1):32-7. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer Lee J11,?Park JO,?Kim WS,?Lee SI,?Song SY,?Lim DH,?Choi SH,?Heo JS,?Lee KT,?Lee JK,?Kim K,?Jung CW,?Im YH,?Lee MH,?Kang WK,?Park K.
    View PubMed
  • Bone Marrow Transplant. 2003 Nov;32(9):889-95. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia Park J11, Lee MH, Lee HR, Park SH, Lee SH, Lee KE, Lee H, Park JO, Kim K, Jung CW, Im YH, Kang WK, Ko YH, Park K.
    View PubMed
  • Jpn J Clin Oncol. 2003 Oct;33(10):533-7. Measuring response in solid tumors: Comparison of RECIST and WHO response criteria Park JO11, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Lee KS, Park K.
    View PubMed